Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}
COVID-19 Response & Business Continuity
Employee Health & Safety How We Are Fighting COVID-19 Latest News Business Continuity and Customer Letters External Research Program Resources

Our COVID-19 Response

Terumo BCT and Terumo Corporation, our parent company, are actively responding to the current outbreak of coronavirus disease (COVID-19).
This includes focusing on the health and safety of our employees, maintaining a strong product supply, growing our external research program, and leveraging our resources and technologies in the fight against COVID-19.
In all cases, our response is guided by our mission: Contributing to Society Through Healthcare.

Employee Health & Safety

Our utmost priority is the continued health and well-being of our 7,100 employees worldwide.

How We Are Fighting COVID-19

Learn how we are actively engaged in and contributing to the global efforts for the prevention and treatment of COVID-19.

Convalescent Plasma

People who have recovered from a virus like COVID-19 have antibodies to the disease in their blood. Through a simple transfusion process, those same antibodies can be shared with others who have the virus so they, too, can better fight the disease.

Read More  

Pathogen Reduction

A new study shows Terumo BCT's Mirasol Pathogen Reduction Technology (PRT) System is effective against the virus that causes COVID-19 when high virus levels are present in human plasma and platelets. This system is designed to add an extra layer of safety to the blood supply.1

Read More  

Acute Respiratory Distress Syndrome

A study is underway to show how Terumo's Spectra Optia® Apheresis System and Marker Therapeutics Depuro D2000 Adsorption Cartridges can reduce cytokine storms in COVID-19 patients' blood.2

Watch Now  

Latest News

First Lady of Ghana Encourages Healthy Ghanaians to Become Champions of Change and Donate Blood to Save Lives  

Queen Mothers' workshop to help build community capacity and reverse 80% drop in blood collections in Ghana due to COVID-19

Webinar Summary: Selective Removal of Inflammatory Cytokines With the Spectra Optia and D2000 Column  

Under an emergency use authorization from the FDA, Terumo Blood and Cell Technologies and Marker Therapeutics AG are working together in up to 15 U.S. sites to treat patients in the ICU with severe COVID-19. View and share this summary or the link to the on-demand recording of the webinar.

A Look Inside Terumo BCT's Impact on Convalescent Plasma for COVID-19   

What is convalescent plasma? And is it effective in fighting COVID-19?

Terumo BCT’s Mirasol reduces the virus causing COVID-19 below the limit of detection in plasma and platelets  

Vox Sanguinis, a peer-reviewed medical journal, published results from a Terumo BCT study conducted in collaboration with top researchers at Colorado State University. The study examined how well the Mirasol system treated platelets and plasma against the virus causing COVID-19.

Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide  

Terumo Corporation is donating USD 2.4 million in cash and products to support the novel coronavirus disease relief efforts worldwide – including a USD 1 million donation to the COVID-19 Solidarity Response Fund for WHO.

Terumo BCT and Marker Therapeutics received the first device FDA Emergency Use Authorization (EUA) to treat acute respiratory failure in COVID-19 patients  

“We thank the Food and Drug Administration for their expedited review, which provides another treatment option for patients in the ICU to help reduce the severity of the disease,” says Antoinette Gawin, CEO and President of Terumo BCT, and David Cohen, Chairman of Marker.

1The Mirasol PRT system is not approved for sale in the U.S. 

2FDA Required Disclaimers:

  • The Spectra Optia Apheresis System with the Depuro D2000 Adsorption Cartridge has been neither cleared nor approved for the indication to treat patients with COVID-19 infection;
  • The Spectra Optia Apheresis System with the Depuro D2000 Adsorption Cartridge has been authorized by FDA under an EUA;
  • The Spectra Optia Apheresis System with the Depuro D2000 Adsorption Cartridge is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the Spectra Optia Apheresis System with the Depuro D2000 Adsorption Cartridge under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Business Continuity and Customer Letters

We are exercising maximum effort to maintain a stable supply of products to meet healthcare needs.

Customer Letter: Update on Terumo BCT Global Supply Chain and Logistics in Response to the Novel Coronavirus (SARS-CoV-2) Pandemic  

Terumo BCT has a comprehensive and established Business Continuity Policy in place, designed to safeguard our associates around the world and our ability to deliver products worldwide.

Terumo BCT has strong business continuity plans to help ensure continued availability of our products that are used to treat critically ill patients and that collect and process blood and blood products. We know a safe, sustainable and readily available supply of blood is vital to those with serious conditions and diseases.

View business continuity infographic

Download Business Continuity Infographic

External Research Program for Investigator-Initiated Studies

Discovery never stops. We share a passion for thinking in new and different ways and support COVID-19 studies around the globe with scientific and medical merit developed by independent investigators or academic sponsors around the globe. Visit our External Research Program (ERP) for more information.


{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }}
{{$index+1}}. {{s.label}}